At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 4 enrolled
Drug / intervention
Rosiglitazone and Bexarotenedrug
Likely dose
Rosiglitazone added to bexarotene capsules (dose not specified)AI-extracted
Key inclusion· 6
- ✓Biopsy-proven persistent or recurrent cutaneous T-cell lymphoma (CTCL) stages IA through IVA
- ✓Patient has been taking Targretin (bexarotene) for at least 4 months with stable dosing
- ✓Stable or progressive disease over the past 4 months
- ✓ECOG performance status 0-2
Key exclusion· 8
- ✕CD30-positive anaplastic large cell lymphoma
- ✕Peripheral T-cell lymphoma diagnosis
- ✕Stage IVB disease (visceral involvement)
- ✕History of HIV, hepatitis B, or hepatitis C infection
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open Label Pilot Study of Combination Therapy With Rosiglitazone and Bexarotene to Investigate a Possible Synergism in the Treatment of Cutaneous T-Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Rosiglitazone and Bexarotene for Cutaneous T-cell Lymphoma and 2 related conditions. Completed, enrolled 4 participants across 1 site.
Detailed Summary
The purpose of this trial is to determine if combination therapy with rosiglitazone and bexarotene might have a synergistic effect in the treatment of patients with CTCL.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2005
First PostedSep 2005
Primary CompletionMar 2007
TodayJul 2026
First PostedSep 15, 2005
Enrollment StartJun 1, 2005
Primary CompletionMar 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 20.8 years ago
Interventions
Rosiglitazone and Bexarotenedrug
rosiglitazone added to bexarotene capsules